首页> 外国专利> METHOD FOR PROGNOSTICATING THE CLINICAL RESPONSE OF A PATIENT TO B-LYMPHOCYTE INHIBITING OR DEPLETING THERAPY IN INTERFERON DRIVEN DISEASES SUCH AS SLE

METHOD FOR PROGNOSTICATING THE CLINICAL RESPONSE OF A PATIENT TO B-LYMPHOCYTE INHIBITING OR DEPLETING THERAPY IN INTERFERON DRIVEN DISEASES SUCH AS SLE

机译:预知患者对SLE干扰素驱动疾病抑制或消减B淋巴细胞的临床反应的方法

摘要

The invention relates to methods for predicting a clinical response to B- lymphocyte inhibiting or depleting therapies (BCIDT) using expression levels of genes of the Type I INF pathway. In another aspect, the invention relates to a method for evaluating a pharmacological effect of a treatment with B- lymphocyte inhibiting or depleting therapy. More in particular, the invention relates to a method for prognosticating the clinical response of a patient to treatment with a soluble BCID or TCID agent, said method comprising the steps of obtaining at least two samples from said patient wherein a first sample has not been exposed to a soluble BCID or TCID agent and wherein at least a second sample has been exposed to a soluble BCID or TCID agent, determining the level of an IFN (preferably type I) response in said at least two samples, comparing the level of the IFN (preferably type I) response in said first sample with the level of the IFN (preferably type I) response in said at least second sample and prognosticating said clinical response from said comparison.
机译:本发明涉及使用I型INF途径的基因的表达水平来预测对B淋巴细胞抑制或耗竭疗法(BCIDT)的临床反应的方法。在另一方面,本发明涉及一种评估用B淋巴细胞抑制或耗竭疗法治疗的药理作用的方法。更具体地,本发明涉及一种预后患者对用可溶性BCID或TCID剂治疗的临床反应的方法,所述方法包括从所述患者获得至少两个样品的步骤,其中第一样品未暴露相对于可溶性BCID或TCID剂,并且其中至少第二个样品已暴露于可溶性BCID或TCID剂中,确定所述至少两个样品中的IFN(优选I型)应答水平,比较IFN的水平所述第一样品中的(优选I型)应答与所述至少第二样品中的IFN(优选I型)应答水平并根据所述比较预后所述临床应答。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号